Dare Bioscience Investor Presentation Deck
●
FDA Approved - XACIATO
NDA approved December 7, 2021
QIDP, Fast Track and Priority Review Designations
●
XACIATO™ (Clindamycin Phosphate) Vaginal Gel, 2%
XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% is a lincosamide antibacterial
indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older.*
This marks the first FDA-approved product in Daré's portfolio of potential first-in-category
development candidates.
XACIATO is expected to be available commercially in the U.S. in 4Q 2022.
*See Full Prescribing Information for the safe and effective use of XACIATO.
*See important safety information on slides 20 and 21.
Commercialization Collaborator
ORGANON
• The license became effective June 2022.
• Daré received a $10 million upfront
payment from Organon in 3Q 2022.
Daré is eligible to receive potential
milestone payments of up to $182.5
million and tiered double-digit royalties
based on net sales.
9View entire presentation